Definitive Contract 75N91018C00031
Award Date 9/17/18
Potential Completion Date 12/16/19
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Pottstown, PA 19464, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Firm Fixed Price contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Abzyme Therapeutics LLC, a minority-owned small business, under the Small Business Innovation Research (SBIR) program. The objective of the $299,815.00 Phase I contract is to develop camelid variable heavy chain antibody fragments (VHH) that can significantly enhance the expression of the HIV envelope glycoprotein gp120 in mammalian cells, enabling rapid and...
- This federal contract award, valued at $149,964.61, was made by the Joint Program Executive Office for Chemical and Biological Defense, a U.S. Department of Defense organization, to Abzyme Therapeutics LLC, a small, minority-owned, for-profit limited liability company. The contract was awarded under the Small Business Innovation Research (SBIR) program, Phase I, and is a firm-fixed-price purchase order. The contract supports research and development work by Abzyme Therapeutics related to...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Abzyme Therapeutics LLC, a minority-owned biopharmaceutical company. The contract, valued at $999,998.10, is for research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. The contract is a Firm Fixed Price Definitive Contract, and the place of performance is...
- This contract was awarded to Abzyme Therapeutics LLC, a small business, by the Joint PEO Chemical and Biological Defense, which is a defense agency. The contract is a Small Business Innovation Research (SBIR) Program Phase I award with a firm fixed price of $149,656.59 and a period of performance through January 13, 2018. The contract is focused on research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. Abzyme Therapeutics LLC is a...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued at $299,937, was awarded to Vitan-Biotech LLC, a minority-owned for-profit biotechnology company, to develop single domain antibodies for the detection and imaging of modified RNA nucleosides. This research aligns with NCI's mission to advance...
- This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
- This is a $300,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Base Pair Biotechnologies Inc., a for-profit company that provides custom aptamer development services and products to the federal government. The contract is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics", which was one of the research topics identified in the...
- This $199,987 fixed-price contract was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Avantgen Inc., a small business biotechnology company based in San Diego, California. The contract is for the development of recombinant rabbit monoclonal antibodies to be used as affinity captures for peptides. This work supports the agency's research and development efforts in cancer immunotherapy. The contract was set aside for small businesses and has a period...
- This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
- This is a SBIR Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to Detroit R&D, Inc., a small business. The $147,520.00 fixed-price contract is for the development of glycosylation-specific research reagents, specifically antibodies and aptamers, under SBIR Topic 294. The contract was awarded on September 15, 2011 and has a completion date of December 14, 2012. Detroit R&D, Inc. is a minority-owned, for-profit,...